Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
JP Casazza, EM Cale, S Narpala, GV Yamshchikov… - Nature medicine, 2022 - nature.com
Adeno-associated viral vector-mediated transfer of DNA coding for broadly neutralizing anti-
HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination …
HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination …
Host anti-antibody responses following adeno-associated virus–mediated delivery of antibodies against HIV and SIV in rhesus monkeys
JM Martinez-Navio, SP Fuchs, S Pedreño-López… - Molecular Therapy, 2016 - cell.com
Long-term delivery of antibodies against the human immunodeficiency virus (HIV) using
adeno-associated virus (AAV) vectors is a promising approach for the prevention or …
adeno-associated virus (AAV) vectors is a promising approach for the prevention or …
Long-term delivery of an anti-SIV monoclonal antibody with AAV
JM Martinez-Navio, SP Fuchs, DE Mendes… - Frontiers in …, 2020 - frontiersin.org
Long-term delivery of anti-HIV monoclonal antibodies using adeno-associated virus (AAV)
holds promise for the prevention and treatment of HIV infection. We previously reported that …
holds promise for the prevention and treatment of HIV infection. We previously reported that …
Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression
JM Martinez-Navio, SP Fuchs, SN Pantry, WA Lauer… - Immunity, 2019 - cell.com
Long-term delivery of anti-HIV monoclonal antibodies (mAbs) using adeno-associated virus
(AAV) vectors holds promise for the prevention and treatment of HIV infection. We describe a …
(AAV) vectors holds promise for the prevention and treatment of HIV infection. We describe a …
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial
FH Priddy, DJM Lewis, HC Gelderblom, H Hassanin… - The Lancet …, 2019 - thelancet.com
Background A preventive vaccine for HIV is a crucial public health need; adeno-associated
virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to …
virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to …
Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention
JM Brady, D Baltimore, AB Balazs - Immunological reviews, 2017 - Wiley Online Library
Broadly neutralizing antibodies (bNA bs) against human immunodeficiency virus (HIV) show
great promise in HIV prevention as they are capable of potently neutralizing a considerable …
great promise in HIV prevention as they are capable of potently neutralizing a considerable …
AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity
SP Fuchs, JM Martinez-Navio, M Piatak Jr… - PLoS …, 2015 - journals.plos.org
Long-term delivery of potent broadly-neutralizing antibodies is a promising approach for the
prevention of HIV-1 infection. We used AAV vector intramuscularly to deliver anti-SIV …
prevention of HIV-1 infection. We used AAV vector intramuscularly to deliver anti-SIV …
Anti-drug antibody responses impair prophylaxis mediated by AAV-delivered HIV-1 broadly neutralizing antibodies
MR Gardner, I Fetzer, LM Kattenhorn… - Molecular Therapy, 2019 - cell.com
Adeno-associated virus (AAV) delivery of potent and broadly neutralizing antibodies (bNAbs
is a promising approach for the prevention of HIV-1 infection. The immunoglobulin G (IgG) 1 …
is a promising approach for the prevention of HIV-1 infection. The immunoglobulin G (IgG) 1 …
Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors
Adeno-associated viruses (AAV) have attracted attention as potential vectors for gene
therapy and vaccines against several diseases, including HIV-1 infection. However, the …
therapy and vaccines against several diseases, including HIV-1 infection. However, the …
Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort
DP Perocheau, SC Cunningham, J Lee… - Human gene …, 2019 - liebertpub.com
Recombinant adeno-associated virus (rAAV) vectors are a promising platform for in vivo
gene therapy. The presence of neutralizing antibodies (Nab) against AAV capsids …
gene therapy. The presence of neutralizing antibodies (Nab) against AAV capsids …